Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Бевацизумаб при распространенном раке яичников: когда, зачем и почему?
Бевацизумаб при распространенном раке яичников: когда, зачем и почему?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Лечение распространенного рака яичников (РЯ) до сих пор остается непростой задачей, продолжая вызывать интерес у исследователей. Поскольку стандартная цитостатическая терапия не меняется в течение последних 20 лет, добавление таргетных препаратов к терапии 1-й линии является одним из перспективных подходов. В настоящее время наиболее изучена группа антиангиогенных препаратов, а бевацизумаб является одним из самых активно исследуемых таргетных препаратов. В данной работе рассматриваются результаты последних исследований, а также новые возможности и перспективы для назначения бевацизумаба при распространенном РЯ.
Ключевые слова: рак яичников, антиангиогенная терапия, таргетная терапия, бевацизумаб.
Key words: ovarian cancer, anti-angiogenic therapy, targeted therapy, bevacizumab.
Ключевые слова: рак яичников, антиангиогенная терапия, таргетная терапия, бевацизумаб.
________________________________________________
Key words: ovarian cancer, anti-angiogenic therapy, targeted therapy, bevacizumab.
Полный текст
Список литературы
1. Тюляндин С.А., Покатаев И.А., Тюляндина А.С. и др. Лечение распространенного рака яичников: итоги работы отделения клинической фармакологии и химиотерапии РОНЦ РАМН им. Н.Н.Блохина за 1993–2010 гг. М.: Вестн. РАМН, 2011; 12: 4–9.
2. Armstrong D, Bundy B, Wenzel L et al. Phase III randomized trial of intravenous cisplatin and paclitaxel vs an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006; 354: 34–43.
3. Bansal G, Shulimovich M, Ratnarajah G et al. Clinical benefit and toxicity of continuing bevacizumab containing chemotherapies in patients with recurrent ovarian cancer. Cancer Therapy 2012; 8: 184–90.
4. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29–37.
5. Burger RA, Brady MF, Bookman MA et al. The incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–83.
6. Chan J, Brady JM, Penson R et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin ± bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
7. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab treated patients with metastatic colorectal cancer: results from ARIES observational cohort study and confirmation of BRiTE data on BV beyond progression. J Clin Oncol 2010; 28 (Suppl. 15s). Abstr. 3596.
8. du Bois A et al. AGO-OVAR 12: a randomized placebo-controlled gcig/engot-intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
9. Ebos J, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232–9.
10. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579–91.
11. Fabi A, Russillo M, Ferretti G et al. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012; 12: 1–7.
12. Gore M, Harrias M. Chemotherapy for epithelial ovarian cancer – treatment at first diagnosis. The Lancet Oncol 2002; 3: 529–36.
13. Gridelli C, Bennouna J, Castro J et al. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer 2011; 12 (6): 407–11.
14. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326–34.
15. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.
16. Jayson G, Hicklin D, Ellis L et al. Antiangiogenic therapy – evolving view based on clinical trial results. Nat Rev Clin Oncol 2012; 14 (9): 297–303.
17. Kassim SK, El-Salahy EM, Fayed ST et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37 (5): 363–9.
18. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331–8.
19. Masi G, Loupakis F, Salvatore L et al. Second-line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who progressed to a first-line treatment containing bevaizunab: Updated results of the phase III BEBYP trial by the Gruppo Oncologico Nord Ovest. JCO 2013; 31. Abstr. 3615.
20. Mancuso M, Davis R, Norberg S et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Ivest 2006; 116 (10): 2610–21.
21. Mannocci A, De Feo E, de Waure C et al. Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of pub-lished studies. Tumori 2010; 96: 385–91.
22. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851–6.
23. McCann GA, Smith B, Backes FJ et al. Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecologic Oncol 2012; 127: 362–6.
24. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92.
25. Oza AM, Perren TJ, Swart AM et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer 2013; 49 (Suppl. 3): LBA6.
26. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected III stage, ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.
27. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220–31.
28. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484–96.
29. Pignata S, Scambia G, Lauria R et al. A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin plus paclitaxel in patients with advanced ovarian cancer: multicentre Italian trial on ovarian cancer (MITO-7): European Network of Gynecological Oncological Trial Group (ENGOT-ov-10). Gynecologic Cancer Inter Group (GCIG) trial. J Clin Oncol 2013; 31. Abstr. LBA 5501.
30. Press JZ, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA 1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
31. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum – Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. JCO 2014; 32 (13): 1302–8.
32. von Minckwitz G, Schwedler K, Schmidt M et al. Final overall survival analysis of the TBP phase III study (GBG 26/BIG 3-05): capecitabine vs capecitabine trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment. Cancer Res 2010; 70 (Suppl. 24): 459s. Abstr. P6-14-05.
2. Armstrong D, Bundy B, Wenzel L et al. Phase III randomized trial of intravenous cisplatin and paclitaxel vs an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006; 354: 34–43.
3. Bansal G, Shulimovich M, Ratnarajah G et al. Clinical benefit and toxicity of continuing bevacizumab containing chemotherapies in patients with recurrent ovarian cancer. Cancer Therapy 2012; 8: 184–90.
4. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29–37.
5. Burger RA, Brady MF, Bookman MA et al. The incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–83.
6. Chan J, Brady JM, Penson R et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin ± bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
7. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab treated patients with metastatic colorectal cancer: results from ARIES observational cohort study and confirmation of BRiTE data on BV beyond progression. J Clin Oncol 2010; 28 (Suppl. 15s). Abstr. 3596.
8. du Bois A et al. AGO-OVAR 12: a randomized placebo-controlled gcig/engot-intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
9. Ebos J, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232–9.
10. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579–91.
11. Fabi A, Russillo M, Ferretti G et al. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012; 12: 1–7.
12. Gore M, Harrias M. Chemotherapy for epithelial ovarian cancer – treatment at first diagnosis. The Lancet Oncol 2002; 3: 529–36.
13. Gridelli C, Bennouna J, Castro J et al. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer 2011; 12 (6): 407–11.
14. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326–34.
15. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.
16. Jayson G, Hicklin D, Ellis L et al. Antiangiogenic therapy – evolving view based on clinical trial results. Nat Rev Clin Oncol 2012; 14 (9): 297–303.
17. Kassim SK, El-Salahy EM, Fayed ST et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37 (5): 363–9.
18. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331–8.
19. Masi G, Loupakis F, Salvatore L et al. Second-line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who progressed to a first-line treatment containing bevaizunab: Updated results of the phase III BEBYP trial by the Gruppo Oncologico Nord Ovest. JCO 2013; 31. Abstr. 3615.
20. Mancuso M, Davis R, Norberg S et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Ivest 2006; 116 (10): 2610–21.
21. Mannocci A, De Feo E, de Waure C et al. Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of pub-lished studies. Tumori 2010; 96: 385–91.
22. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851–6.
23. McCann GA, Smith B, Backes FJ et al. Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecologic Oncol 2012; 127: 362–6.
24. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92.
25. Oza AM, Perren TJ, Swart AM et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer 2013; 49 (Suppl. 3): LBA6.
26. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected III stage, ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.
27. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220–31.
28. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484–96.
29. Pignata S, Scambia G, Lauria R et al. A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin plus paclitaxel in patients with advanced ovarian cancer: multicentre Italian trial on ovarian cancer (MITO-7): European Network of Gynecological Oncological Trial Group (ENGOT-ov-10). Gynecologic Cancer Inter Group (GCIG) trial. J Clin Oncol 2013; 31. Abstr. LBA 5501.
30. Press JZ, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA 1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
31. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum – Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. JCO 2014; 32 (13): 1302–8.
32. von Minckwitz G, Schwedler K, Schmidt M et al. Final overall survival analysis of the TBP phase III study (GBG 26/BIG 3-05): capecitabine vs capecitabine trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment. Cancer Res 2010; 70 (Suppl. 24): 459s. Abstr. P6-14-05.
Авторы
А.С.Тюляндина
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.